- Settlement ends all existing claims between ResMed and BMC/3B Medical
- BMC and 3B will pay royalties to ResMed
- ResMed makes one-time payment to 3B to resolve Florida litigation
SAN DIEGO – January 20, 2017 – ResMed (NYSE:RMD), BMC (Beijing, China) and 3B Medical (Winter Haven, Florida) today announced they have agreed on a global settlement of all litigation between the parties. BMC and 3B will be permitted to sell their existing products in exchange for royalty payments to ResMed, and ResMed will make a one-time settlement payment to 3B to close the Florida litigation between the two parties. The settlement did not include an admission of liability or wrongdoing by any party.
The five-year agreement between the three companies resolves all pending litigation before the U.S. International Trade Commission, lawsuits pending in district court in Florida and California, foreign litigation in China and Germany, and validity challenges pending in various patent offices around the world.
“We are pleased to bring our litigation with BMC and 3B to a resolution and to have our intellectual property and patents recognized through this settlement,” said David Pendarvis, ResMed’s Global General Counsel. “For 28 years, ResMed has stood strong in its commitment to innovate and develop products and solutions that exceed the needs of our HME customers and the patients we serve together. This agreement allows us to continue the important work we are doing for the patients and providers who count on us to provide the best products for treating the world’s most serious respiratory conditions. And it allows us to avoid the distraction and ongoing expense of continued litigation.”
“We are equally pleased to bring global litigation with ResMed to a resolution. The settlement allows 3B Medical to innovate and provide alternative solutions to the sleep-disordered breathing marketplace,” said Alex Lucio, Executive Vice President of 3B Medical.
“BMC continues to develop its own portfolio of intellectual property as one of the global manufacturers in the sleep-disordered breathing market. We continue to fund research and development and bring new products to market. This agreement brings a very long battle with ResMed to a final conclusion and allows all of our companies to focus on developing great products to service the needs of our patients,” said James Xu, General Manager of BMC Medical.
ResMed (NYSE:RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 2 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world’s best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries.
About BMC Medical/3B
3B/BMC is a global leader in the research and development, manufacturing and marketing of medical products for the diagnosis, treatment and management of sleep disordered breathing.
# # #
For media: Alison Graves | 858.836.6789 | firstname.lastname@example.org
For investors: Agnes Lee | 858.836.5971 | email@example.com
For media: Rebecca Velazquez | 893.226.6285 | RVelazquez@3Bproducts.com